A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Aim: Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Molecular-based patient stratification for identification of resistant patients, who will benefit from alternative tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Issa Ismail, Brøndum, Rasmus Froberg, Due, Hanne, Schmidt, Linnéa, Bøgsted, Martin, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019184/
https://www.ncbi.nlm.nih.gov/pubmed/35582014
http://dx.doi.org/10.20517/cdr.2020.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019184/
https://www.ncbi.nlm.nih.gov/pubmed/35582014
http://dx.doi.org/10.20517/cdr.2020.76

Ejemplares similares